CorMedix/CRMD

$5.44

0.37%
-
1D1W1MYTD1YMAX

About CorMedix

CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.

Ticker

CRMD

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Joseph Todisco

Employees

82

Headquarters

Berkeley heights, United States

CorMedix Metrics

BasicAdvanced
$299.1M
Market cap
-
P/E ratio
-$0.92
EPS
1.77
Beta
-
Dividend rate
$299.1M
1.77293
$7.00
$2.57
555.92K
6.969
6.784
-64.32%
-74.02%
-73.33%
4.261
4.264
-100%
-24.35%

What the Analysts think about CorMedix

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 4 analysts.
138.97% upside
High $19.00
Low $9.00
$5.44
Current price
$13.00
Average price target

CorMedix Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-14.7M
51.55%
Profit margin
0%
-

CorMedix Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 28.87%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.24
-$0.25
-$0.17
-$0.26
-
Expected
-$0.20
-$0.24
-$0.21
-$0.20
-$0.28
Surprise
20%
3.59%
-18.17%
28.87%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for CorMedix stock?

CorMedix (CRMD) has a market cap of $298M as of April 21, 2024.

What is the P/E ratio for CorMedix stock?

The price to earnings (P/E) ratio for CorMedix (CRMD) stock is 0 as of April 21, 2024.

Does CorMedix stock pay dividends?

No, CorMedix (CRMD) stock does not pay dividends to its shareholders as of April 21, 2024.

When is the next CorMedix dividend payment date?

CorMedix (CRMD) stock does not pay dividends to its shareholders.

What is the beta indicator for CorMedix?

CorMedix (CRMD) has a beta rating of 1.77. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the CorMedix stock price target?

The target price for CorMedix (CRMD) stock is $13, which is 146.21% above the current price of $5.28. This is an average based on projections from 4 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell CorMedix stock

Buy or sell CorMedix stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing